Publications

5674 Results

Predicting Severe Toxicities with Intensive Induction Chemotherapy for Adult Acute Myeloid Leukemia: Analysis of SWOG Trials S0106 and S1203

Authors
A Moseley;M Othus;G Garcia-Manero;F Appelbaum;H Erba;R Walter
Journal / Conference
Leukemia and Lymphoma Jul;62(7):1774-1777
Year
2021
Research Committee(s)
Leukemia
PMID
PMID33560164
PMC
PMC8282671
Study Number(s)
S0106, S1203

Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation [Care Delivery Review]

Authors
C Eng;E Chen;J Rogers;M Lewis;J Strosberg;R Thota;S Krishnamurthi;P Oberstein;R Govindarajan;G Buchschacher;S Patel;D Sohal;T Al-Toubah;P Philip;NA Dasari;H Kennecke;S Stein
Journal / Conference
JCO Oncology Practice
Year
2021
Research Committee(s)
Cancer Care Delivery
PMID
PMID33534616
PMC
PMC8791825

A Phase II Study of Talazoparib in Patients with Homologous Recombination Repair Deficiency (HRRD) Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study S1400G)

Authors
T Owonikoko;M Redman;L Byers;F Hirsch;P Mack;L Schwartz;J Bradley;T Stinchcombe;N Lleighl;T Al Baghdadi;P Lara;J Miao;K Kelly;S Ramalingam;R Herbst;V Papadimitrakopoulou;D Gandara
Journal / Conference
Clinical Lung Cancer May;22(3):187-194.e1. doi: 10.1016/j.cllc.2021.01.001. Epub 2021 Jan 10.
Year
2021
Research Committee(s)
Lung
PMID
PMID33583720
PMC
PMC8637652
Study Number(s)
S1400G

A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695)

Authors
T Flaig;C Tangen;S Daneshmand;A Alva;S Lerner;M Lucia;D McConkey;D Theodorescu;A Goldkorn;M Milowsky;R Bangs;G MacVicor;B Bastos;J Fowles;D Gustafson;M Plets;I Thompson
Journal / Conference
Clinical Cancer Research May 1;27(9):2435-2441; Feb 10;clincanres.2409.2020. doi: 10.1158/1078-0432.CCR-20-2409. Online ahead of print
Year
2021
Research Committee(s)
Genitourinary
PMID
PMID33568346
PMC
PMC8219246
Study Number(s)
S1314

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial

Authors
D Sohal;M Duong;S Ahmad;N Gandhi;S Beg;A Wang-Gillam;JL Wade;EG Chiorean;K Guthrie;A Lowy;P Philip;H Hochster
Journal / Conference
JAMA Oncology Mar 1;7(3):421-427. doi: 10.1001/jamaoncol.2020.7328.
Year
2021
Research Committee(s)
Gastrointestinal
PMID
PMID33475684
PMC
PMC7821078
Study Number(s)
S1505

Genetic architectures of proximal and distal colorectal cancer are partly distinct

Authors
J Huyghe;T Harrison;S Bien;H Hampel;Figueriedo;S Schmit;D Albanes;P Goodman;C Tangen;S Gruber;L Hsu;V Moreno;R Hayes;P Newcomb;P Ulrike
Journal / Conference
Gut Jul;70(7):1325-1334; Feb 25;gutjnl-2020-321534. doi: 10.1136/gutjnl-2020-321534. Online ahead of print
Year
2021
Research Committee(s)
Prevention, Screening, and and Surveillance
PMID
PMID33632709
PMC
PMC8223655
Study Number(s)
S0000

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

Authors
A Advani;E Larsen;K Laumann;S Luger;M Liedtke;M Devidas;Z Chen;Z Chen;J Yen;M Foster;D Claxton;K Coffan;M Tallman;F Appelbaum;H Erba;H Erba;R Stone;S Hunger;J McNeer;M Loh;E Raetz;N Winick;W Carroll;R Larson;W Stock
Journal / Conference
Blood Advances Jan 26;5(2):504-512. doi: 10.1182/bloodadvances.2020002439.
Year
2021
Research Committee(s)
Leukemia
PMID
PMID33496745
PMC
PMC7839367
Study Number(s)
C10403

Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin

Authors
A List;Z Sun;A Verma;J Bennett;R Komrokji;K McGraw;L Nardelli;J Maciejewski;J Altman;P Cheema;D Claxton;S Luger;R Mattison;T Wassenaar;A Artz;C Schiffer;M Litzow;M Tallman
Journal / Conference
Journal of Clinical Oncology Mar 20;39(9):1001-1009
Year
2021
Research Committee(s)
Leukemia
PMID
PMID33439748
PMC
PMC8274743
Study Number(s)
CTSU/E2905

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412

Authors
G Nowakowski;F Hong;D Scott;W Macon;R King;T Habermann;M Wagner-Johnston;C Casulo;JL Wade, III;G Nagargoje;C Reynolds;J Cohen;N Khan;J Amengual;K Richards;R Little;J Leonard;JW Friedberg;L Kostakoglu;B Kahl;T Witzig
Journal / Conference
Journal of Clinical Oncology Apr 20;39(12):1329-1338. doi: 10.1200/JCO.20.01375. Epub 2021 Feb 8.
Year
2021
Research Committee(s)
Lymphoma
PMID
PMID33555941
PMC
PMC8078264
Study Number(s)
CTSU/E1412

Midostaurin reduces the cumulative incidence of relapse and is tolerable for maintenance in FLT3-mutant acute myeloid leukemia (CALGB 10603)

Authors
RA Larson;S Mandrekar;L Huebner;B Sanford;C Laumann;S Geyer;C Bloomfield;C Thiede;T Prior;K Dohner;G Marcucci;M Voso;R Klisovic;I Galinsky;A Wei;J Sierra;M Sanz;J Brandwein;T de Witte;D Niederwieser;F Appelbaum;B Medeiros;M Tallman;J Krauter;R Schlenk;R Ganser;H Serve;G Ehninger;S Amadori;I Gathmann;H Dohner;R Stone
Journal / Conference
Blood Sep;35(9):2539-2551
Year
2021
Research Committee(s)
Leukemia
PMID
PMID33654204
PMC
PMC8591906
Study Number(s)
CTSU/C10603